Claudia Ordonez - 11 Jun 2021 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Role
Chief Medical Officer
Signature
/s/ Keith Regnante, Attorney-in-Fact
Issuer symbol
KROS
Transactions as of
11 Jun 2021
Net transactions value
-$50,510
Form type
4
Filing time
15 Jun 2021, 17:01:06 UTC
Previous filing
13 May 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KROS Common Stock Options Exercise $480 +1,000 $0.4800* 1,000 11 Jun 2021 Direct
transaction KROS Common Stock Sale $32,963 -653 -65% $50.48 347 11 Jun 2021 Direct F1, F2
transaction KROS Common Stock Sale $18,027 -347 -100% $51.95 0 11 Jun 2021 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KROS Employee Stock Option (right to buy) Options Exercise $0 -1,000 -1% $0.000000 98,211 11 Jun 2021 Common Stock 1,000 $0.4800 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.15 to $51.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.63 to $52.21 inclusive.
F4 One-quarter (1/4th) of the shares subject to the option shall vest on September 16, 2020, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.